Maria Luisa Belli
Overview
Explore the profile of Maria Luisa Belli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
192
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parisi E, Arpa D, Ghigi G, Fabbri L, Foca F, Tontini L, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831400
Malignant Pleural Mesothelioma (MPM) is a rare malignancy with an overall poor prognosis. The standard therapeutic strategy in early-stage disease is trimodality therapy. In this publication, we report the preliminary...
2.
Mezzenga E, Piccinini F, Loi E, Belli M, Sarnelli A
Sci Data
. 2022 Jul;
9(1):412.
PMID: 35840608
In a clinical contest, it is common to use dedicated phantoms to perform quality assurance test to check the performance of a SPECT system. Some of these phantoms are also...
3.
Sarnelli A, Belli M, Azzali I, Loi E, Severi S, Strigari L
Cancers (Basel)
. 2022 Feb;
14(4).
PMID: 35205825
Previously published studies combined external beam radiotherapy (EBRT) treatments with different activities of Ra. The data of two-year overall survival (2y-OS) and neutropenia (TOX) incidence when combining EBRT and Ra...
4.
Cicone F, Sarnelli A, Guidi C, Belli M, Ferrari M, Wahl R, et al.
Semin Nucl Med
. 2022 Jan;
52(2):191-214.
PMID: 34996594
Radioimmunotherapy (RIT) is a safe and active treatment available for non-Hodgkin lymphomas (NHLs). In particular, two monoclonal antibodies raised against CD20, that is Zevalin (Y-ibritumomab-tiuxetan) and Bexxar (I-tositumomab) received FDA...
5.
Fantini L, Belli M, Azzali I, Loi E, Bettinelli A, Feliciani G, et al.
Front Oncol
. 2021 Jul;
11:601053.
PMID: 34249671
Purpose: The objective of this study was to evaluate a set of radiomics-based advanced textural features extracted from F-FLT-PET/CT images to predict tumor response to neoadjuvant chemotherapy (NCT) in patients...
6.
Belli M, Sarnelli A, Mezzenga E, Cesarini F, Caroli P, Di Iorio V, et al.
Front Oncol
. 2020 Nov;
10:531660.
PMID: 33251129
Radioligand therapy is a type of internal radiotherapy combining a short-range radioisotope labeled to a carrier with a high affinity for a specific receptor expressed on tumor cells. Targeted alpha...
7.
Schumacher-Kuckelkorn R, Atra A, Belli M, Den Engelsman G, Freneaux P, Gauthier A, et al.
Pediatr Blood Cancer
. 2020 Nov;
68(3):e28819.
PMID: 33245195
Background: The quantitative assessment of neuroblastoma cell content in bone marrow aspirates for response evaluation has been introduced recently. Data on the concordance of interobserver reports are lacking so far....
8.
Paganelli G, Sarnelli A, Severi S, Sansovini M, Belli M, Monti M, et al.
Eur J Nucl Med Mol Imaging
. 2020 May;
47(13):3008-3017.
PMID: 32430583
Purpose: Radioligand therapy (RLT) with Lu-PSMA-617 is a promising option for patients with metastatic castration-resistant prostate cancer (mCRPC). The present study was designed to define the safety and initial response...
9.
Belli M, Mezzenga E, Di Iorio V, Celli M, Caroli P, Canali E, et al.
J Vis Exp
. 2020 May;
(158).
PMID: 32391816
Peptide-receptor-radionuclide-therapy (PPRT) is a targeted therapy that combines a short-range energy radionuclide with a substrate with high specificity for cancer cell receptors. After injection, the radiotracer is distributed throughout the...
10.
Raggi F, Cangelosi D, Becherini P, Blengio F, Morini M, Acquaviva M, et al.
J Transl Med
. 2020 Jan;
18(1):21.
PMID: 31924244
Background: Tetralogy of Fallot (ToF) and Atrial Septal Defects (ASD) are the most common types of congenital heart diseases and a major cause of childhood morbidity and mortality. Cardiopulmonary bypass...